IMV (OTCPK:IMVI.Q) - Stock Price, News & Analysis

IMVI.Q Stock Overview

IMV Inc. operates as a clinical-stage immuno-oncology company.

IMVI.Q fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Rewards

Risk Analysis

Latest financial reports are more than a year old

Shares are highly illiquid

Negative shareholders equity

Makes less than USD$1m in revenue ($0)

+ 1 more risk

IMV Inc. Competitors

Plant-Based Investment

OTCPK:CWWB.F

US$27.0

PLx Pharma Winddown

OTCPK:PLXP.Q

US$30.0

Genocea Biosciences

OTCPK:GNCA.Q

US$5.9k

RVL Pharmaceuticals

OTCPK:RVLP.Q

US$111.0

Price History & Performance

Summary of all time highs, changes and price drops for IMV
Historical stock prices
Current Share Price	US$0.000001
52 Week High	US$0.85
52 Week Low	US$0.000001
Beta	0.75
1 Month Change	-90.00%
3 Month Change	-99.95%
1 Year Change	-100.00%
3 Year Change	-100.00%
5 Year Change	-100.00%
Change since IPO	-100.00%

Recent updates

IMV T cell therapy shows positive action in treatment-resistant ovarian cancer; shares up 5%

Dec 03

IMV reports Q3 results

Nov 12

Shareholder Returns

	IMVI.Q	US Biotechs	US Market
7D	0%	1.0%	1.2%
1Y	-100.0%	0.7%	24.9%

Price Volatility

Is IMVI.Q's price volatile compared to industry and market?
IMVI.Q volatility
IMVI.Q Average Weekly Movement	n/a
Biotechs Industry Average Movement	11.6%
Market Average Movement	6.0%
10% most volatile stocks in US Market	16.6%
10% least volatile stocks in US Market	3.0%

Stable Share Price: IMVI.Q's share price has been volatile over the past 3 months.

Volatility Over Time: Insufficient data to determine IMVI.Q's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2000	63	Andrew Hall	www.imv-inc.com

IMV Inc. operates as a clinical-stage immuno-oncology company. The company develops a portfolio of therapies based on DPX its immune-educating technology platform for treatment of solid and hematological cancers. The company’s lead drug candidate includes maveropepimut-S, a DPX-based immunotherapy that targets survivin-expressing cells that is Phase II clinical trials for diffuse large B cell lymphoma; ovarian cancer; and bladder, liver, and MSI-H solid tumors, as well as in Phase I clinical trial for breast cancer.

IMV Inc. Fundamentals Summary

How do IMV's earnings and revenue compare to its market cap?
IMVI.Q fundamental statistics
Market cap	US$11.00
Earnings (TTM)	-US$37.99m
Revenue (TTM)	n/a

0.0x

P/S Ratio

0.0x

P/E Ratio

Is IMVI.Q overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
IMVI.Q income statement (TTM)
Revenue	US$0
Cost of Revenue	US$23.28m
Gross Profit	-US$23.28m
Other Expenses	US$14.71m
Earnings	-US$37.99m

Last Reported Earnings

Dec 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)	-3.24
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	-415.9%

How did IMVI.Q perform over the long term?

See historical performance and comparison

IMVI.Q Stock Overview

Rewards

Risk Analysis

IMV Inc. Competitors

OTCPK:CWWB.F

US$27.0

OTCPK:PLXP.Q

US$30.0

OTCPK:GNCA.Q

US$5.9k

OTCPK:RVLP.Q

US$111.0

Price History & Performance

Recent News & Updates

IMV Inc. Files Form 15

Nasdaq to Delist the Common Shares of IMV

IMV Inc.(OTCPK:IMVI.Q) dropped from NASDAQ Composite Index

IMV Receives Nasdaq Delisting Notice

IMV Inc. Presents Positive Initial Results from the MVP-S Phase 2B Vitalize Trial

High number of new directors

Recent updates

IMV Inc. Files Form 15

Nasdaq to Delist the Common Shares of IMV

IMV Inc.(OTCPK:IMVI.Q) dropped from NASDAQ Composite Index

IMV Receives Nasdaq Delisting Notice

IMV Inc. Presents Positive Initial Results from the MVP-S Phase 2B Vitalize Trial

High number of new directors

IMV Inc. Announces Board Changes

IMV Inc. has completed a Follow-on Equity Offering in the amount of $9 million.

IMV Inc. has completed a Follow-on Equity Offering in the amount of $9 million.

Imv Inc. Announces Initial Data from the Ongoing Phase 2B Vitalize Trial in Patients with R/R Dlbcl

IMV Inc. to Report Q3, 2022 Results on Nov 11, 2022

IMV Inc. Announces Board Changes

IMV to cut ~33% workforce amid reorganization

High number of new directors

IMV Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

IMV receives Nasdaq non-compliance letter

High number of new directors

IMV Inc. Announces Andrew Sheldon Not Stand for Re-Election to the Board

IMV Inc. announced that it has received $25 million in funding from Horizon Technology Finance Management, LLC

IMV Inc. Appoints Michael P. Bailey as Chairman of the Board

IMV Inc., Annual General Meeting, Jun 14, 2022

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

IMV Announces First Patient Dosed in the VITALIZE Phase 2B Clinical Study Evaluating its Lead Compound, MVP-S, in Combination with KEYTRUDA® (pembrolizumab) in Patients with r/r DLBCL

IMV Inc Announces Finalization of the Basket Clinical Study in Collaboration with Merck and Reveals Promising Top Line Data from the Bladder and MSI-High Cohorts

IMV Inc. announces new translational data implicating B cells in the clinical benefit induced by MVP-S treatment in ovarian cancer patients

IMV Inc. Announces First Patient Dosed in Phase 1b Clinical Study Evaluating its Lead Compound in Patients with Breast Cancer

IMV Inc. Announces Final Topline Results of the Decide1 Clinical Trial

CEO & Director Frederic Ors has left the company

High number of new directors

CEO & Director recently bought US$147k worth of stock

Chief Medical Officer Joanne Schindler has left the company

IMV names Jeremy Graff as chief scientific officer

Imv Inc. Leads Immunotherapy to Be Investigated in Breast Cancer

Independent Director has left the company

Full year 2020 earnings released: CA$0.58 loss per share (vs CA$0.55 loss in FY 2019)

IMV Inc. to Report Q4, 2020 Results on Mar 17, 2021

New 90-day high: US$4.36

IMV Reports Update on COVID-19 Vaccine Program

IMV's vaccine candidate potentially effective against COVID-19, shares up 16%

New 90-day low: US$3.13

Durable Clinical Benefits Induced by IMV’s T Cell Therapy in Combination With Merck’s Keytruda in Subjects With PD-L1 Positive r/r DLBCL Presented at ASH Annual Meeting

IMV’s Survivin-Targeted T Cell Therapy Shows Durable Clinical Benefits in Phase 2 Study in Patients with Hard-to-Treat Advanced Recurrent Ovarian Cancer

IMV T cell therapy shows positive action in treatment-resistant ovarian cancer; shares up 5%

Revenue and earnings beat expectations

IMV reports Q3 results

IMV Inc. Appoints Andrew Hall as Chief Business Officer

IMV's T Cell Therapy Demonstrates 86% Objective Response Rate in Combination with Merck's Keytruda® in PD-L1 Positive Patients with r/r DLBCL

IMV Inc. Provides Updated Clinical Data from Phase 2 SPiReL Study Evaluating its T Cell Therapy in Combination with Merck’s Keytruda in Patients with R/R DLBCL

New 90-day low: US$3.15

IMV Inc Announces That Biomarkers Associated with Clinical Response in Patients with R/R DLBCL Treated with DPX-Survivac

New 90-day low: US$3.85

IMV Inc. Provides Updates on Its Vaccine Candidate, DPX-COVID-19, for the Prevention of Infection Caused by the Novel Coronavirus SARS-COV-2

Earnings released

IMV Inc. to Report Q2, 2020 Results on Aug 12, 2020

Shareholder Returns

Price Volatility

About the Company

IMV Inc. Fundamentals Summary

0.0x